FDA Approves Priovant’s LISRAYA for Dermatomyositis, First Targeted Therapy for Rare Disease
Event summary
- FDA approved Priovant Therapeutics' LISRAYA (brepocitinib) as the first targeted therapy for adult dermatomyositis on August 27, 2026.
- Approval based on Phase 3 VALOR trial showing clinically meaningful improvements in disease activity.
- Dermatomyositis, a rare autoimmune disease, previously lacked targeted treatments, relying on broad immunosuppressants.
- MDA highlights the milestone as proof of progress in rare disease research and precision therapies.
The big picture
The approval marks a shift toward precision therapies in rare autoimmune diseases, reducing reliance on broad immunosuppressants. MDA’s role in accelerating therapeutic development highlights the growing momentum in neuromuscular research. The success of targeted therapies like LISRAYA could reshape treatment paradigms for similar conditions.
What we're watching
- Market Expansion
- Whether Priovant can leverage this approval to expand into other rare neuromuscular diseases.
- Clinical Adoption
- The pace at which dermatomyositis patients transition from broad immunosuppressants to LISRAYA.
- Pipeline Momentum
- How this success influences MDA’s investment in neuromuscular research and clinical trials.
Related topics